Clifford Chance advised Keymed Biosciences on the deal. Keymed Biosciences (HKSe: 02162) signed a licensing agreement granting Platina the exclusive worldwide rights to develop, manufacture and...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Keymed Biosciences on the deal. Timberlyne Therapeutics, Inc. announced its US$180 million Series A financing to advance the development of CM313. Investors Abingworth,...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on the deal. Keymed Biosciences (Chengdu) Co., Ltd. completed an out-licensing transaction with Belenos Biosciences, Inc.to exclusively...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Spectris Plc on the deal. Spectris plc (SXS: LSE), the expert in providing insight through precision measurement, has agreed to acquire SciAps Incorporated...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised LiveOak Fiber on the deal. LiveOak Fiber, a regional broadband service provider founded in 2022, has secured $250 million in financing underwritten...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Hitachi Ltd. on the deal. Hitachi Ltd. has signed a stock purchase agreement to acquire all shares of MA micro automation GmbH from...
You must be a Standard 1 Year member to access this content.
Leading international law firm Clifford Chance advised iStar Inc. in the deal. iStar Inc. (iStar), a publicly traded real estate finance and investment company, complete its...
You must be a Standard 1 Year member to access this content.
